Liposomal doxorubicin (Myocet ® ) with cyclophosphamide for first-line therapy of metastatic breast cancer in patient previously treated with anthracyclines in the adjuwant setting

Abstract

The anthracycline doxorubicin is among the most active dugs in breast cancer and included in chemotherapy regimens for all stages of breast cancer treatment. However, re-treatment with doxorubicin in metastatic disease is limited by a cumulative dose-dependent cardiotoxicity. Liposomal doxorubicin (Myocet^®) is less cadiotoxic than doxorubicin with proven efficacy in metastatic breast cancer. In this case report Myocet^® in combination with cyclophosphamide was used for first-line therapy of metastatic breast cancer in patient after doxorubicin-containing therapy as adjuvant treatment.
Onkol. Prak. Klin. 2010; supl. A: A25–A27